

Australian Technical Advisory Group on Immunisation (ATAGI) recommended COVID-19 vaccines and doses

The table below summarises the Australian Technical Advisory Group on Immunisation (ATAGI) recommendations relating to COVID-19 vaccines and required doses for the general population.

GROUP	VACCINES	PRIMARY COURSE	BOOSTER	FOURTH DOSE
GENERAL POPULATION				
5 years	Pfizer (COMIRNATY) (For Ages 5 to <12)	FIRST DOSE → SECOND DOSE	Not approved or recommended.	Not approved or recommended.
6 – 11 years	Pfizer (COMIRNATY) (For Ages 5 to <12) Moderna (SPIKEVAX) [^]	FIRST DOSE → SECOND DOSE	Not approved or recommended.	Not approved or recommended.
12 – 15 years	Pfizer (COMIRNATY) Moderna (SPIKEVAX)	FIRST DOSE → SECOND DOSE	Pfizer (COMIRNATY): approved but not recommended. Moderna (SPIKEVAX): not approved or recommended	Not approved or recommended.
16 – 17 years	Pfizer (COMIRNATY)* Moderna (SPIKEVAX)	FIRST DOSE → SECOND DOSE	BOOSTER <i>ONLY PFIZER APPROVED</i> 3 months after Primary Course	Not approved or recommended.
18 – 29 years	Pfizer (COMIRNATY) Moderna (SPIKEVAX) Novavax (NUVAXOVID)** AstraZeneca (VAXZEVRIA)	FIRST DOSE → SECOND DOSE	BOOSTER 3 months after Primary Course	Not approved or recommended.
30- 49 years	Pfizer (COMIRNATY) Moderna (SPIKEVAX) Novavax (NUVAXOVID)** AstraZeneca (VAXZEVRIA)	FIRST DOSE → SECOND DOSE	BOOSTER 3 months after Primary Course	FOURTH DOSE From 3 months after Booster
50+ years	Pfizer (COMIRNATY) Moderna (SPIKEVAX) Novavax (NUVAXOVID)** AstraZeneca (VAXZEVRIA)	FIRST DOSE → SECOND DOSE	BOOSTER 3 months after Primary Course	FOURTH DOSE From 3 months after Booster

Notes

[^] There is no separate paediatric formulation of the Moderna vaccine – children aged 6 to 11 years receive half the adult dose (50µg in 0.25 mL). ATAGI recommends that providers are vigilant about the potential for dosing errors, including overdosing, with the Moderna vaccine in children.

* For people aged 12 to 17 years, Pfizer COVID-19 vaccine is the only vaccine registered for use as a booster.

** Novavax can only be used as a booster if no other COVID-19 vaccine is suitable.

Information current as of 7 July 2022. Detailed information on ATAGI clinical guidelines for administration of COVID-19 vaccines is available at: www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance/clinical-recommendations

Australian Technical Advisory Group on Immunisation (ATAGI) recommended COVID-19 vaccines and doses

The table below summarises the Australian Technical Advisory Group on Immunisation (ATAGI) recommendations relating to COVID-19 vaccines and required doses for special populations.

GROUP	VACCINES	PRIMARY COURSE	BOOSTER	FOURTH DOSE
SPECIAL POPULATIONS				
5 years severely immunocompromised	Pfizer (COMIRNATY) (For Ages 5 to <12)	FIRST DOSE → SECOND DOSE → THIRD DOSE Third dose 2 months after second dose	Not approved or recommended.	Not approved or recommended.
6 – 11 years severely immunocompromised	Pfizer (COMIRNATY) (For Ages 5 to <12) Moderna (SPIKEVAX) [^]	FIRST DOSE → SECOND DOSE → THIRD DOSE Third dose 2 months after second dose	Not approved or recommended.	Not approved or recommended.
12 – 15 years severely immunocompromised	Pfizer (COMIRNATY) Moderna (SPIKEVAX)	FIRST DOSE → SECOND DOSE → THIRD DOSE Third dose 2 months after second dose	BOOSTER ONLY PFIZER APPROVED 3 months after Primary Course	Not approved or recommended.
16 – 17 years severely immunocompromised	Pfizer (COMIRNATY)* Moderna (SPIKEVAX)	FIRST DOSE → SECOND DOSE → THIRD DOSE Third dose 2 months after second dose	BOOSTER ONLY PFIZER APPROVED 3 months after Primary Course	FOURTH DOSE ONLY PFIZER APPROVED From 3 months after Booster
18+ years severely immunocompromised	Pfizer (COMIRNATY) Moderna (SPIKEVAX) Novavax (NUVAXOVID)** AstraZeneca (VAXZEVRIA)	FIRST DOSE → SECOND DOSE → THIRD DOSE Third dose 2 months after second dose	BOOSTER 3 months after Primary Course	FOURTH DOSE From 3 months after Booster
12 – 15 years who have a disability with significant or complex health needs, or who have complex and/or multiple health conditions that increase the risk of severe COVID-19 [%]	Pfizer (COMIRNATY)* Moderna (SPIKEVAX)	FIRST DOSE → SECOND DOSE	BOOSTER ONLY PFIZER APPROVED 3 months after Primary Course	Not approved or recommended.
Pregnant, breastfeeding or planning pregnancy	Pfizer (COMIRNATY)* Moderna (SPIKEVAX) Novavax (NUVAXOVID)** (18+) AstraZeneca (VAXZEVRIA) (18+)	FIRST DOSE → SECOND DOSE	BOOSTER 3 months after Primary Course	Not approved or recommended.
Residents of aged care or disability care facilities aged 16+ years	Pfizer (COMIRNATY)* Moderna (SPIKEVAX) Novavax (NUVAXOVID)** (18+) AstraZeneca (VAXZEVRIA) (18+)	FIRST DOSE → SECOND DOSE	BOOSTER 3 months after Primary Course	FOURTH DOSE From 3 months after Booster
People aged 16 – 29 years who have complex, chronic or severe conditions that are considered to increase their risk of severe illness from COVID-19 [#]	Pfizer (COMIRNATY)* Moderna (SPIKEVAX) Novavax (NUVAXOVID)** (18+) AstraZeneca (VAXZEVRIA) (18+)	FIRST DOSE → SECOND DOSE	BOOSTER 3 months after Primary Course	FOURTH DOSE From 3 months after Booster

Notes

[^] There is no separate paediatric formulation of the Moderna vaccine – children aged 6 to 11 years receive half the adult dose (50µg in 0.25 mL). ATAGI recommends that providers are vigilant about the potential for dosing errors, including overdosing, with the Moderna vaccine in children.

* For people aged 12 to 17 years, Pfizer COVID-19 vaccine is the only vaccine registered for use as a booster.

** Novavax can only be used as a booster if no other COVID-19 vaccine is suitable.

[%] Refer to 'ATAGI recommendations on first booster dose in adolescents aged 12-15 years' for more information: <https://www.health.gov.au/news/atagi-recommendations-on-first-booster-dose-in-adolescents-aged-12-15-years>

[#] Refer to Table 1 in the 'ATAGI Expanded ATAGI recommendations on fourth COVID-19 booster doses for people at increased risk of severe COVID-19': www.health.gov.au/resources/publications/expanded-atagi-recommendations-on-winter-covid-19-booster-doses-for-people-at-increased-risk-of-severe-covid-19 The examples are not exhaustive and providers may include individuals with conditions similar to those listed below, based on clinical judgment.

Information current as of 7 July 2022. Detailed information on ATAGI clinical guidelines for administration of COVID-19 vaccines is available at: www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance/clinical-recommendations